Primary Health Care: Open Access

ISSN - 2167-1079

Valeria P

Valeria P
Eli lilly and Company,

  • Review Article
    A New Approach to Drug Therapy: Fc-Fusion Technology
    Author(s): Valeria P, Chrisanthi AK, Luis-Emilio GP and Wolfgang GValeria P, Chrisanthi AK, Luis-Emilio GP and Wolfgang G

    Fc-fusion proteins have been successfully implemented in the treatment of many diseases. Advances in engineering and design of these therapeutic proteins have helped prolong the drug half-life, which in turn allows for longer dosing intervals (i.e. weekly or bi-weekly administration) and, thus, may improve patient adherence in a real world setting. In this review, we provide a brief summary of half-life extension technologies. Here, we focus on IgG-Fc fusion and the key roles that the Fc fragment plays in both physiology and drug therapy, and the potential to elicit immune responses in humans. This review provides examples of various recombinant Fc-fusion protein drugs, including, etanercept (Enbrel®) for the treatment of various forms of arthritis, aflibercept (Eylea®), for the treatment of neovascular age-related macular degeneration and dulaglutide (Trulicity™) for .. View More»

    DOI: 10.4172/2167-1079.1000255

    Abstract PDF

Relevant Topics